List of companies in TF Capital (Shanghai)'s investment portfolio
Name | Description | Industry | Official Website | Location | ||
|---|---|---|---|---|---|---|
Antengene is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. | ||||||
Abogen Biosciences is a China-based company. | ||||||
EOC Pharma Group is an in licensing for Chinese market founded in 1948 by Xin Ni. | ||||||
GenFleet Therapeutics is a small and Large Molecules founded in 2017 by Qiang Lu. | ||||||
ShouTi Inc. is a Shanghai-based company founded in 2019. | ||||||
Askgene Pharma is a company founded in 2012. | ||||||
Abbisko Therapeutics is an immunomodulators for cancer founded in 2016. | ||||||
Regor Therapeutics is a computer Accelerated Rational Discovery founded in 2018. | ||||||
Xgene Pharmaceutical is a Shanghai-based company founded in 2016 by Feng Xu. | ||||||
Avenzo Therapeutics is a San Diego-based company founded by Athena Countouriotis. | ||||||
Yuesai Biotechnology is a Pudong-based company founded in 2021. | ||||||
Chemsemi is a Yangzhou-based company founded in 2020. | ||||||
UniXell is a Shanghai-based company. | ||||||
GeneQuantum Healthcare is a company founded in 2013. | ||||||
CytoLynx Therapeutics is a Shanghai-based company founded in 2021 by Laura Hong. | ||||||
Minghui Pharmaceutical is a Shanghai-based, late-stage biopharmaceutical company pioneering next-generation immuno-oncology therapies, including PD-1/VEGF bispecifics, IGF-1R inhibitors, and its lead B7-H3 ADC (MHB088C). In mid-2025, it secured USD 186 million licensing plus milestone and royalty payments from Qilu Pharma for Greater China rights. |
